-
Increased mumps incidence in the Netherlands: Review on the possible role of vaccine strain and genotype
-
View Affiliations Hide AffiliationsP Kaaijkpatricia.kaaijk nvi-vaccin.nl
-
View Citation Hide Citation
Citation style for this article: . Increased mumps incidence in the Netherlands: Review on the possible role of vaccine strain and genotype . Euro Surveill. 2008;13(26):pii=18914. https://doi.org/10.2807/ese.13.26.18914-en Received: 23 Jun 2008
- Previous Article
- Table of Contents
- Next Article
Abstract
As reported in a recent issue of Eurosurveillance, a mumps outbreak is ongoing in the Netherlands despite high vaccination coverage of 90-95% [1]. The reported mumps cases are restricted to geographic regions with a high percentage of residents who are members of a religious community that rejects vaccination. Consequently, two thirds of the mumps patients were not vaccinated. However, also vaccinated individuals in these regions were affected [1]. Since 1987, the measles-mumps-rubella (MMR) combination vaccine produced by the Netherlands Vaccine Institute (NVI) is part of the Dutch national immunisation programme and administered at the ages of 14 months and nine years.
![Loading full text...](/images/jp/spinner.gif)
Full text loading...
![](/images/commenting/icon_checkmark.png)